Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Susan Elaine Yost"'
Autor:
Yuan Yuan, Jianying Zhang, Jonathan Kessler, Jamie Rand, Badri Modi, Shyambabu Chaurasiya, Mireya Murga, Aileen Tang, Norma Martinez, Hans Meisen, Dave Yamauchi, Susan Elaine Yost, Leslie Mi Ok Chong, Amanda Seiz, Bonnie Nixon, Nicholas Ede, James Ross Waisman, Daphne B. Stewart, Joanne E. Mortimer, Yuman Fong
Publikováno v:
Journal of Clinical Oncology. 40:e13070-e13070
e13070 Background: Despite recent FDA approval of immune checkpoint inhibitor pembrolizumab and drug-antibody conjugate in the treatment of metastatic triple negative breast cancer (mTNBC), the overall survival benefit of these therapies remains mode
Autor:
Yuan Yuan, Xuan Ge, Susan Elaine Yost, Jin Sun Lee, Paul Henry Frankel, Christopher Ruel, Yujie Cui, Mireya Murga, Aileen Tang, Norma Martinez, Misagh Karimi, George Somlo, Joanne E. Mortimer, James Ross Waisman
Publikováno v:
Journal of Clinical Oncology. 40:e13071-e13071
e13071 Background: Pembrolizumab (pembro) in combination with chemotherapy (chemo) has recently become standard of care in patients with programmed death-ligand 1 (PD-L1) positive metastatic triple negative breast cancer (mTNBC). Optimal chemo partne
Autor:
Weihua Guo, Colt A. Egelston, Katherine E. Hutchinson, Jennifer M. Giltnane, Veronica Ibarra-Lopez, Bonnie Liu, Susan Elaine Yost, Daniel Schmolze, Peter P. Lee, Yuan Yuan
Publikováno v:
Journal of Clinical Oncology. 40:1079-1079
1079 Background: Immune checkpoint inhibitors (ICI) have improved PFS and OS in metastatic triple-negative breast cancer (mTNBC), but benefit is limited to PD-L1 positive tumors. Metastatic tumors are notorious for deficient immune cell infiltration
Autor:
Xuan Ge, Susan Elaine Yost, Jin Sun Lee, Paul Henry Frankel, Christopher Ruel, Yujie Cui, Mireya Murga, Aileen Tang, Norma Martinez, Samuel Chung, Christina Haeyoung Yeon, Daphne B. Stewart, Daneng Li, Swapnil Padmakar Rajurkar, George Somlo, Joanne E. Mortimer, James Ross Waisman, Yuan Yuan
Publikováno v:
Journal of Clinical Oncology. 40:1053-1053
1053 Background: Aromatase inhibitor (AI) is standard of care for patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). The current phase I trial was designed to test t